Prof Andrew Tutt speaks to ecancer in an online interview for the virtual ASCO 2021 meeting about the OlympiA study.
Prof Tutt explains that the phase III study looked at the addition of one year of the PARP inhibitor olaparib for the treatment of patients with high-risk early-stage HER2-negative breast cancer with BRCA 1/2 mutations who have received adjuvant or neoadjuvant chemotherapy, surgery and any radiation therapy required.
He reports that olaparib significantly improved disease-free survival in these patients and, while the patients continue to be followed up to determine overall survival and long-term safety endpoints, the study has met the criteria to be considered by the regulatory agencies as a potential new therapeutic strategy.
Prof Tutt notes that another important finding from the study was the importance of testing for germline mutations, as this can both help to determine treatment options as well as providing insight into familial risk.
Read more about the study here.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.